M
Michael B. Sporn
Researcher at Dartmouth College
Publications - 561
Citations - 96644
Michael B. Sporn is an academic researcher from Dartmouth College. The author has contributed to research in topics: Transforming growth factor & Transforming growth factor beta. The author has an hindex of 157, co-authored 559 publications receiving 94605 citations. Previous affiliations of Michael B. Sporn include Cornell University & Reata Pharmaceuticals.
Papers
More filters
Journal ArticleDOI
Isolation from murine sarcoma cells of novel transforming growth factors potentiated by EGF
Anita B. Roberts,Mario A. Anzano,Lois C. Lamb,J M Smith,Charles A. Frolik,H. Marquardt,George J. Todaro,Michael B. Sporn +7 more
TL;DR: The ability to enhance the growth-stimulating effects of the TGFs is specific to EGF, as insulin, the insulin-like growth factors, platelet-derived growth factor and nerve growth factor do not show this property.
Journal ArticleDOI
Loss of expression of transforming growth factor beta in skin and skin tumors is associated with hyperproliferation and a high risk for malignant conversion
Adam B. Glick,Ashok B. Kulkarni,Tamar Tennenbaum,Henry Hennings,Kathleen C. Flanders,Michael A. O'Reilly,Michael B. Sporn,Stefan Karlsson,Stuart H. Yuspa +8 more
TL;DR: TGF- beta expression and function are compartmentalized in epidermis and epidermal tumors and that loss of TGF-beta is an early, biologically relevant risk factor for malignant progression is shown.
Journal ArticleDOI
A Synthetic Triterpenoid, 2-Cyano-3,12-dioxooleana-1,9-dien-28-oic Acid (CDDO), Is a Ligand for the Peroxisome Proliferator-Activated Receptor γ
Yongping Wang,Weston W. Porter,Nanjoo Suh,Tadashi Honda,Gordon W. Gribble,Lisa M. Leesnitzer,Kelli D. Plunket,David J. Mangelsdorf,Steven G. Blanchard,Timothy M. Willson,Michael B. Sporn +10 more
TL;DR: The triterpenoid CDDO is established as a member of a new class of PPARgamma ligands, and synergizes with a retinoid X receptor (RXR)-specific ligand to induce 3T3-L1 differentiation, while CDDO-Me is an antagonist in this assay.
Journal Article
Prevention of Breast Cancer in the Rat with 9-cis-Retinoic Acid as a Single Agent and in Combination with Tamoxifen
Mario A. Anzano,Stephen W. Byers,Joseph A. M. Smith,Christopher W. Peer,Larry T. Mullen,Charles C. Brown,Anita B. Roberts,Michael B. Sporn +7 more
TL;DR: For suppression of carcinogenesis in vivo, 9cRA was much more potent than all-trans-retinoic acid, both as a single agent or in combination with TAM, although both retinoids had equivalent inhibitory effects on DNA synthesis in cultured human breast cancer cell lines.
Journal ArticleDOI
Novel triterpenoid CDDO-Me is a potent inducer of apoptosis and differentiation in acute myelogenous leukemia
Marina Konopleva,Twee Tsao,Peter P. Ruvolo,Irina Stiouf,Zeev Estrov,Clinton E. Leysath,Shourong Zhao,David J. Harris,Shirong Chang,C. Ellen Jackson,Mark F. Munsell,Nanjoo Suh,Gordon W. Gribble,Tadashi Honda,W. Stratford May,Michael B. Sporn,Michael Andreeff +16 more
TL;DR: CDDO-Me is an MDR-1- and a p53-independent compound that exerts strong antiproliferative, apoptotic, and differentiating effects in myeloid leukemic cell lines and in primary AML samples when given in submicromolar concentrations.